X0306 4 2020-12-22 0 0001445283 YUMANITY THERAPEUTICS, INC. YMTX 0001834469 Epstein Marie C/O YUMANITY THERAPEUTICS, INC 40 GUEST STREET, SUITE 4410 BOSTON MA 02135 0 1 0 0 Principal Accounting Officer Stock Option (Right to Buy) 8.16 2020-12-22 4 A 0 38373 A 2028-12-03 Common Stock 38373 38373 D Stock Option (Right to Buy) 8.16 2020-12-22 4 A 0 4216 A 2030-02-17 Common Stock 4216 4216 D On August 22, 2020, the Issuer (formerly known as Proteostasis Therapeutics, Inc.) entered into an Agreement and Plan of Merger and Reorganization, as amended on November 6, 2020, with Pangolin Merger Sub, Inc. ("Merger Sub"), Yumanity, Inc. (formerly known as Yumanity Therapeutics, Inc.) and Yumanity Holdings, LLC ("Holdings"). On December 22, 2020, Merger Sub was merged with and into Yumanity, Inc., with Yumanity, Inc. surviving as a wholly-owned subsidiary of the Issuer (the "Merger"). Immediately prior to the consummation of the Merger, Holdings was merged with and into Yumanity, Inc., with Yumanity, Inc. as the surviving entity. 25% of the shares subject to the option vested on July 31, 2019. The remaining 75% vest in equal monthly installments over the subsequent three years. Received in the Merger in exchange for a stock option to acquire 182,000 shares of Yumanity, Inc. common stock for $1.72 per share. 25% of the shares subject to the option vest on February 18, 2021. The remaining 75% vest in equal monthly installments over the subsequent three years. Received in the Merger in exchange for a stock option to acquire 20,000 shares of Yumanity, Inc. common stock for $1.72 per share. /s/ Marie Epstein 2020-12-28